Madeline Ziegler
Adult Health · Goshen, NYNPI 1154874139
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 302 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,879, 9.2 times the $204 reported in 2021. Among adult health clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$912
- AstraZeneca$745
- Novo Nordisk$537
- Boehringer Ingelheim$465
- Pfizer$265
- plus $1K from 23 others
What the payments were for
- Food & beverage$5,639100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 55 | $1,229 |
| Lilly USA, LLC | 63 | $912 |
| AstraZeneca | 39 | $745 |
| Novo Nordisk | 31 | $537 |
| Boehringer Ingelheim | 26 | $465 |
| Pfizer | 13 | $265 |
| GSK | 11 | $244 |
| Exact Sciences | 8 | $183 |
| Gilead | 2 | $142 |
| Amgen(2 entities) | 5 | $114 |
| Merck | 6 | $96 |
| Phathom Pharmaceuticals, Inc. | 8 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $68 |
| Amarin Pharma, Inc. | 4 | $64 |
| Axsome Therapeutics, Inc. | 3 | $52 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Johnson & Johnson | 3 | $45 |
| Medtronic | 2 | $42 |
| Eisai Inc. | 2 | $39 |
| Avanir Pharmaceuticals, Inc. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $32 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Baxter Healthcare | 1 | $25 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yeztugo$125
How this compares
$5,639 in reported general payments places this provider in the 90th percentile of 3,828 adult health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 21 | $33,341 |
| MounjaroTirzepatide | 16 | $24,211 |
| EliquisApixaban | 15 | $22,559 |
| FarxigaDapagliflozin Propanediol | 22 | $15,228 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,767 |
| Levothyroxine Sodium | 143 | $1,666 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,196 |
| Atorvastatin Calcium | 110 | $1,168 |
| Potassium Chloride | 20 | $1,027 |
| Omeprazole | 59 | $937 |
| Metoprolol Succinate | 53 | $878 |
| Rosuvastatin Calcium | 66 | $851 |
| Pantoprazole Sodium | 55 | $848 |
| SynthroidLevothyroxine Sodium | 18 | $839 |
| Pregabalin | 14 | $785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $465 | $33,34121 claims |
| Lilly USA, LLCMounjaro | $912 | $24,21116 claims |
| PfizerEliquis | $265 | $22,55915 claims |
| AstraZenecaFarxiga | $745 | $15,22822 claims |
| GSKBreo Ellipta | $244 | $6,76717 claims |
| AbbVieSynthroid | $1,229 | $83918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,828 adult health providers in New York.
Other adult health in Goshen
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Mary CiechoskiBuffalo$200K
- Jennifer FioriniGlens Falls$151K
- Katelyn McCormackAmherst$131K
- Maria Gigante-BaggettEast Syracuse$92K
- Jane PattersonRochester$66K
- Alyson HartyNew York$65K
- Danielle BrunoPlainview$61K
- Julie PlantamuraPort Jefferson Station$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.